Hubei Jumpcan Pharmaceutical Co., Ltd.

600566

CNE0000018X6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 10/02/2026			5-day change	1st Jan Change
27.20 ^CNY	+0.74%		+5.88%	+3.42%

03/02	Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit	MT
03/02	Jumpcan Pharmaceutical Gets Rights for Pumeixitinib Nasal Spray for 100 Million Yuan	MT

Hubei Jumpcan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.

Published on 11/24/2025

S&P Capital IQ

HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.

+0.74%

The Board of Directors of Hubei Jumpcan Pharmaceutical Co., Ltd. has authorized a buyback plan on November 24, 2025.

Latest news about Hubei Jumpcan Pharmaceutical Co., Ltd.

03/02	Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit	MT
03/02	Jumpcan Pharmaceutical Gets Rights for Pumeixitinib Nasal Spray for 100 Million Yuan	MT
04/01	Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 24, 2025.	CI
24/11	Hubei Jumpcan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	CI
24/11	Hubei Jumpcan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	CI
28/25/28	Jumpcan Pharmaceutical's Q3 Profit Drops 47%, Revenue Falls 33%	MT
27/25/27	Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
17/25/17	Jumpcan Pharma Gets Registration Certificate for Lidocaine Cataplasms	MT
25/25/25	Hubei Jumpcan Pharmaceutical's Attributable Profit Slides 46% in H1; Shares Fall 4%	MT
22/25/22	Hubei Jumpcan Pharmaceutical H1 net profit down 45.9% Y/Y	RE
22/25/22	Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/25/21	Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 23, 2024.	CI
21/25/21	Cao Fei Completes Partial Tender Offer for Jumpcan Pharmaceutical Shares	MT
21/25/21	Jumpcan Pharmaceutical Gets Registration Certificate for Masiloxavir Tablets	MT
21/25/21	Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 22, 2024, has closed with 914,200 shares, representing 0.1% for CNY 25.01 million.	CI
20/25/20	Hubei Jumpcan Pharma's trading to resume	RE
17/25/17	Hubei Jumpcan Pharma's share trade to halt	RE
17/25/17	Cao Fei completed the acquisition of 0.0018% stake in Hubei Jumpcan Pharmaceutical Co., Ltd. for CNY 0.41 million.	CI
08/25/08	Jumpcan Gets Approval for Traditional Chinese Drug for Constipation, Stomach Strengthening	MT
16/25/16	Jumpcan Pharmaceutical Receives Tender Offer Worth 9.45 Billion Yuan	MT
16/25/16	Cao Fei made an offer to acquire 38.2% stake in Hubei Jumpcan Pharmaceutical Co., Ltd. for CNY 8.7 billion.	CI
28/25/28	Hubei Jumpcan Pharmaceutical Co., Ltd. announces Annual dividend, payable on June 30, 2025	CI
25/25/25	Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
02/25/02	Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 23, 2024.	CI
12/25/12	Jumpcan Pharma's Unit Gets Registration Certificate for Sitafloxacin Granules	MT

Chart Hubei Jumpcan Pharmaceutical Co., Ltd.

Duration

Period

Chart Hubei Jumpcan Pharmaceutical Co., Ltd.

600566: Dynamic Chart

HUBEI JUMPCAN PHARMACEUTICAL CO., LTD., formerly Hubei Hongcheng General Machinery Co., Ltd., is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products include heat-clearing and detoxifying series, digestive system series, pediatric series, breathing series, cardiovascular series and gynecology series. Its pharmaceuticals consist of tablets, mixtures, injections, capsules, granules and sprays, among others. The Company mainly distributes its products within domestic markets.

Employees

5,026

Sector

Pharmaceuticals

Calendar

20/04 - Q1 2026 Earnings Release (Projected)

More about the company